1998
DOI: 10.1016/s0167-0115(97)01074-4
|View full text |Cite
|
Sign up to set email alerts
|

Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2000
2000
2017
2017

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 8 publications
0
8
0
Order By: Relevance
“…The synthetic fragments LCRF(1-41) and LCRF(1-35) have similar potency and efficacy for CCK release in conscious rats (134). Tarasova et al (137) reported that endogenous LCRF was present throughout the gut, including in the pancreas, stomach, duodenum, jejunum, ileum, and colon, with the highest concentration in small intestine, supporting the notion that LCRF is secreted into intestinal lumen to stimulate CCK release from mucosal CCK cells.…”
Section: Gut Cck-secreting Cellmentioning
confidence: 92%
“…The synthetic fragments LCRF(1-41) and LCRF(1-35) have similar potency and efficacy for CCK release in conscious rats (134). Tarasova et al (137) reported that endogenous LCRF was present throughout the gut, including in the pancreas, stomach, duodenum, jejunum, ileum, and colon, with the highest concentration in small intestine, supporting the notion that LCRF is secreted into intestinal lumen to stimulate CCK release from mucosal CCK cells.…”
Section: Gut Cck-secreting Cellmentioning
confidence: 92%
“…The amino acid sequence of this peptide was identical to diazepam-binding inhibitor (DBI ) previously purified by Mutt and co-workers [136]. Intraduodenal administration of a fragment of DBI , DBI [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] , in anesthetized and atropinized rats resulted in a dosedependent increase in pancreatic protein secretion and elevation of plasma CCK concentration, although the fragment was less potent than DBI [134]. DBI was also Chey/Chang [138], with permission.…”
Section: Feedback Regulation Of Pancreatic Exocrine Secretionmentioning
confidence: 96%
“…The CCK-RP activity of the partially purified LCRF was abolished when it was percolated through an affinity column made of an anti-LCRF 1-6 serum but not that which was made of a normal rabbit serum [132]. Synthetic fragments of LCRF, LCRF , LCRF , and LCRF [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] , but not LCRF [1][2][3][4][5][6] , were also bioactive [133,134]. Interestingly, intravenous administration of LCRF 1-35 also stimulated CCK release and pancreatic secretion [134].…”
Section: Feedback Regulation Of Pancreatic Exocrine Secretionmentioning
confidence: 99%
“…LCRF was identified after several studies showing that CCK release and pancreatic secretions were inhibited by trypsin, chymotrypsin, and elastases implying an intraluminal factor, sensitive to proteases, that elicits CCK secretion (28). Early studies tested the bioactivity of different LCRF fragments and highlighted the activity of fragment 11–25 but not 1–6 for instance, in accordance with the susceptibility of LCRF bioactivity to intestinal and pancreatic enzymes degradation (29). Further, it has been shown that LCRF acts directly on CCK-secreting cells also via an increase in intracellular calcium at least involving the L-type calcium channel (25).…”
Section: Cck Secretion and Bioactive Peptidesmentioning
confidence: 99%